Hemostemix Inc. (OTCQB: HMTXF) is a patient's own stem cell therapy company that holds 91 patents. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed patented, and is scaling a patient's blood-based stem cell therapeutics platform. Thomas Smeenk, President, CEO and Co-Founder of Hemostemix, joins us today to share his personal story and inspiration for creating this company to help others.